Table 4.
Comparison of dynamic changes in indicator among patients undergoing different treatments
| Index | Operation | Chemotherapy | Target treatment | Combination therapy | F | P |
|---|---|---|---|---|---|---|
| ΔWBC (×109/L) | -1.92±2.19 | 1.19±2.48 | -0.89±2.67 | 1.23±1.91 | 9.959 | 0.000 |
| ΔHGB (g/L) | 17.23±13.49 | 10.69±17.15 | 5.06±16.19 | 10.26±18.21 | 1.248 | 0.295 |
| ΔPLT (109/L) | -49.31±86.82 | 11.95±81.29 | 17.35±61.40 | 35.67±72.92 | 4.193 | 0.007 |
| ΔANC (×109/L) | -2.27±2.16 | 1.15±2.42 | -1.08±2.55 | 1.19±1.87 | 12.456 | 0.000 |
| ΔALC (×109/L) | 0.55±0.36 | 0.03±0.58 | 0.25±0.40 | -0.09±0.57 | 5.300 | 0.002 |
| ΔAMC (×109/L) | -0.13±0.19 | -0.01±0.27 | -0.03±0.21 | -0.00±0.26 | 0.938 | 0.425 |
| ΔNLR (%) | -3.16±2.79 | 0.89±2.95 | -1.96±3.24 | 1.07±2.69 | 11.536 | 0.000 |
| ΔPLR (%) | -86.74±77.10 | 9.29±74.54 | -20.10±92.23 | 49.74±157.98 | 5.445 | 0.001 |
| ΔLMR (%) | 1.79±0.95 | 0.05±2.87 | 0.66±0.99 | 0.22±3.42 | 1.447 | 0.232 |
| ΔALB (g/L) | 3.43±5.00 | -0.33±4.55 | 0.99±5.54 | -1.83±6.99 | 3.266 | 0.024 |
| ΔTC (mmol/L) | 0.47±0.84 | -0.36±0.85 | 0.01±0.63 | -0.35±1.00 | 3.836 | 0.011 |
| ΔTG (mmol/L) | 0.45±0.43 | -0.23±0.65 | -0.07±0.62 | -0.23±1.04 | 2.896 | 0.038 |
| ΔHDL (mmol/L) | 0.05±0.27 | -0.08±0.32 | -0.09±0.55 | -0.11±0.38 | 0.652 | 0.583 |
| ΔLDL (mmol/L) | 0.35±0.73 | -0.23±0.64 | 0.13±0.46 | -0.14±0.70 | 3.566 | 0.016 |
| ΔAPO-A1 (g/L) | 0.18±0.25 | -0.04±0.28 | 0.04±0.35 | -0.07±0.35 | 2.329 | 0.078 |
| ΔAPO-B (g/L) | 0.09±0.19 | -0.05±0.16 | 0.02±0.14 | -0.08±0.22 | 3.549 | 0.016 |
Notes: Δ = (pre-treatment index) - (post-treatment index); WBC, white blood cell; HGB, hemoglobin; PLT, platelets; ANC, absolute neutrophil count; ALC, lymphocyte count; AMC, monocyte count; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; ALB, albumin; TC, cholesterol; TG, triglyceride; HDL, high density lipoprotein; LDL, low density lipoprotein; APO-A1, apolipoprotein A1; APO-B, apolipoprotein B.